New drug ABBV-706 made available for some lung cancer patients before approval
NCT ID NCT07310277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to the investigational drug ABBV-706 for people with small cell lung cancer who have no other treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is given by intravenous infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-706 (intravenous infusion)
- What this could lead to
- If this drug shows benefit, it could offer a new treatment option for patients with small cell lung cancer who have no other suitable therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. The drug is investigational and may not work or could cause side effects. Availability depends on location and eligibility.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a new drug tame advanced solid tumors?
- Can a remote approach bring clinical trials to lung cancer patients?
- Which palliative care approach boosts quality of life in advanced lung cancer?